Effects of salvianolic acid B on liver fibrosis: A protocol for systematic review and meta analysis.
Effects of salvianolic acid B on liver fibrosis: A protocol for systematic review and meta analysis.
复制标题
丹酚酸 B 对肝纤维化的影响：系统评价和荟萃分析方案。
DOI：
10.1097/md.0000000000021036
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Luo Weisheng
中科院分区：
文献类型：
--
作者：
Ma Xiaocong;Tang Meiwen;Lu Liying;Zheng Jinghui;Huang Jingjing;Li Junhong;Luo Weisheng
研究背景：肝纤维化是大多数慢性肝病中存在的一种病理改变，它导致肝脏组织结构的异常改变，影响肝脏的正常生理功能。如果得不到有效控制，肝纤维化可发展为肝硬化，增加肝癌的风险。丹参酸B（Salviridicacid B，Sal B）是丹参水溶性提取物中的主要活性成分，是治疗心血管疾病和肝脏疾病的常用中药。方法：检索PubMed、EMBASE、Web of science、中国知网、中国生物医学文献数据库、万方中文期刊数据库、维普数据库等数据库中的相关研究，并进行统计学分析。检索了从开始到2019年12月的所有数据库。没有语言、出版日期或出版状态的限制。本系统评价的皮科如下：P，评价Sal B对肝纤维化动物模型作用的临床前对照研究，I，单用任何剂量Sal B治疗，C，生理盐水、蒸馏水或不治疗; O，主要结局包括肝纤维化评分的降低，次要结局包括肝纤维化指数。所有纳入的数据将用Review Manager 5.2和STATA 14.2软件进行分析。讨论：本研究的目的是对Sal B抗肝纤维化的作用进行系统评价和Meta分析，为药物开发和病理机制的临床研究做出贡献。INPLASY 202050101，注册日期：2020年5月28日1引言肝纤维化是大多数慢性肝病中存在的一种病理改变，主要表现为肝组织细胞外基质（ECM）过度增生和沉积，从而导致肝脏组织结构发生异常变化，影响肝脏的正常生理功能。[1]如果得不到有效控制，肝纤维化可发展为肝硬化，增加肝癌的风险。[2]事实上，肝纤维化是由多种病因引起的慢性肝损伤的伤口愈合异常的共同结果，并希望得到逆转和治愈。[3]慢性B型肝炎进展为肝硬化的年发病率为2%至10%。[4]因此，积极治疗肝纤维化，逆转或延缓其发展，对提高患者生活质量，改善疾病预后具有重要意义。
Background:Liver fibrosis is a pathological change existing in most chronic liver diseases, which leads to abnormal changes in liver tissue structure and affects the normal physiological function of liver. Without effectively control, liver fibrosis can develop into cirrhosis and increase the risk of liver cancer. Salvianolic acid B (Sal B) is the main active component in the water-soluble extract from Salvia miltiorrhiza, which is a traditional Chinese medicine usually used for treating cardiovascular and liver diseases. It is reported that Sal B shown a good action against liver fibrosis via numerous signaling pathways, which indicate that Sal B is a potential candidate drug for the treatment of liver fibrosis.Methods:We searched the related researches from the following electronic databases: PubMed, EMBASE, Web of science, China National Knowledge Infrastructure (CNKI), China Biology Medicine (CBM), Wan fang Database for Chinese Technical Periodicals and VIP Database. All the databases were searched from inception to December 2019. No restriction of language, publication date, or publication status. PICO of this systematic review are shown as flowing: P, preclinical studies which evaluated the effects of Sal B on the animal models of liver fibrosis with controlled studies; I, received Sal B as only treat in any dose; C, received normal saline, distilled water, or no treatment; O, the primary outcome include measure will be the decrease in liver fibrosis score, and the secondary outcomes include the index of liver fibrosis. All the included data will be analyzed with the software of Review Manager 5.2 and STATA 14.2.Discussion:The purpose of this study is to conduct a systematic review and meta-analysis to assess the effects on anti-liver fibrosis of Sal B, and this will be contribute to drug development and pathological mechanisms of clinical research.Trial registration:INPLASY202050101, registered on 28/5/2020.1 IntroductionLiver fibrosis is a pathological change existing in most chronic liver diseases, mainly manifested as the excessive hyperplasia and deposition of the extracellular matrix (ECM) in liver tissues, which leads to abnormal changes in liver tissue structure and affects the normal physiological function of liver.[1] Without effectively control, liver fibrosis can develop into cirrhosis and increase the risk of liver cancer.[2] In fact, liver fibrosis is a common result of abnormal wound healing of chronic liver injury caused by a variety of etiologies and hoping to be reversed and cured.[3] The annual incidence of chronic hepatitis B progression to cirrhosis is 2% to 10%.[4] Therefore, active treatment of liver fibrosis to reverse or delay its development is of great significance to improve the quality of life of patients and improve the prognosis of the disease.